Patents by Inventor Odile DUVAUX

Odile DUVAUX has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for producing polyclonal antibodies with improved complement-dependent cytotoxicity
    Patent number: 11725044
    Abstract: The present invention relates to polyclonal antibodies directed against at least one non-human biological pathogen, or against at least one molecule derived from said pathogen, towards a human or a non-human animal organism, wherein the said polyclonal antibodies are devoid of an antigenic determinant selected in a group comprising (i) N-glycolneuraminic acid (Neu5Gc) and/or (ii) a-1,3-galactose, and their use as a medicament.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: August 15, 2023
    Assignee: Xenothera
    Inventors: Odile Duvaux, Jean-Paul Soulillou
  • ASSOCIATION OF POLYCLONAL ANTIBODIES AND ANTI-PD1 OR ANTI-PDL1 ANTIBODIES FOR TH TREATMENT OF CANCER
    Publication number: 20220227869
    Abstract: The present invention relates to an association of non-human mammal polyclonal antibodies directed against cancer cells; and at least one monoclonal antibody selected from the group consisting of anti-PD1 and anti-PDL1 monoclonal antibodies for its use for preventing and/or treating a cancer in a mammal patient. The association as such is also considered.
    Type: Application
    Filed: April 28, 2020
    Publication date: July 21, 2022
    Inventors: Odile DUVAUX, Bernard VANHOVE
  • COMPOSITION WITH REDUCED IMMUNOGENICITY
    Publication number: 20170240616
    Abstract: The present invention relates to polyclonal antibodies directed against at least one non-human biological pathogen, or against at least one molecule derived from said pathogen, towards a human or a non-human animal organism, wherein the said polyclonal antibodies are devoid of an antigenic determinant selected in a group comprising (i) N-glycolneuraminic acid (Neu5Gc) and/or (ii) a-1,3-galactose, and their use as a medicament.
    Type: Application
    Filed: October 15, 2015
    Publication date: August 24, 2017
    Applicant: XENOTHERA
    Inventors: Odile DUVAUX, Jean-Paul SOULILLOU